How Does AbZelect™ Improve Cell Line Development Productivity? A Q&A With Simon Keen

By Simon Keen, Scientific Leader, Abzena

Abzena has developed two new cell line development (CLD) platforms, AbZelect™ and AbZelectPRO™, that facilitate the rapid creation and selection of high-yielding mammalian Chinese hamster ovary (CHO) cell lines. These cell lines are vital for the production of therapeutic protein and recombinant vaccines.

Both platforms are optimized across vector, host cell line, and process, delivering improved cell doubling times and viable cell densities, along with robust and stable cell lines. The AbZelect™ platform offers quicker progression to clinical trials, lower production costs, and a built-in risk mitigation strategy. For programs requiring higher titres, such as those for more challenging-to-express proteins, the AbZelectPRO™ platform is ideal.

Discover how both platforms offer cost efficiencies and provide options to de-risk the biologics pathway to Investigational New Drug (IND) application, marking a significant advancement in the field of biologics development.